Showing results (91-100 of 159) with videos related to
Sort By:
Pageof 16
Blood|August 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidineHartmut Döhner, Keith W Pratz, Courtney D DiNardo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication statusJorge E Cortes, Hagop Kantarjian, James M Foran, et al.Blood|February 27, 2016
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cellsSeongseok Yun, Nicole D Vincelette, Katherine L B Knorr, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplantRachel V Hatch, Craig W Freyer, Alison Carulli, et al.Leukemia & Lymphoma|March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemiaMolly E Graveno, Alison Carulli, Craig W Freyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and AzacitidineKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.Japanese Journal of Clinical Oncology|November 5, 2021
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapyKazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E DeZern, Anthony Sung, Sharon Kim, et al.American Journal of Hematology|October 30, 2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult diseaseMark R Litzow, Xin V Wang, Martin P Carroll, et al.Blood|September 27, 2012
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AMLAmy Sexauer, Alexander Perl, Xiaochuan Yang, et al.Pageof 16